Analysis on the dilemma of medical insurance access for chimeric antigen receptor T cell products

LI Shuie, DING Jinxi, LI Jiaming, REN Yuqing, LI Wei

PDF(3695 KB)
主办:上海医药工业研究院
   中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
PDF(3695 KB)
World Clinical Drug ›› 2022, Vol. 43 ›› Issue (04) : 352-358. DOI: 10.13683/j.wph.2022.04.002
Topic

Analysis on the dilemma of medical insurance access for chimeric antigen receptor T cell products

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 43(04): 352-358 https://doi.org/10.13683/j.wph.2022.04.002

References

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(3695 KB)

Accesses

Citation

Detail

Sections
Recommended

/